Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jennifer Bré
Observed name:
Bré, Jennifer
Institutions:
University of St Andrews,
Cambridge Science Centre
Observed institutions:
Lyon 1 Université,
Centre National de la Recherche Scientifique,
Inserm,
University of St Andrews,
Cambridge Science Centre,
Centre Léon Bérard,
Centre de Recherche en Cancérologie de Lyon,
Nucana (United Kingdom)
show all 8
ORCID:
0000-0002-9793-6432
Observed ORCID:
0000-0002-9793-6432
OpenAlex ID:
A5065214450
The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent
2023
·
Jennifer Bré
, Alison L. Dickson
, et al.
·
Cancer Chemotherapy and Pharmacology
·
26
PDF
Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031
2019
·
Awa Sarr
, Jennifer Bré
, et al.
·
Scientific Reports
·
18
PDF
Heparanase-1 is upregulated by hepatitis C virus and favors its replication
2022
·
Christophe Gallard
, Nadjet Lebsir
, et al.
·
Journal of Hepatology
·
17
PDF
Defining the mode of action of cisplatin combined with NUC-1031, a phosphoramidate modification of gemcitabine
2024
·
Dillum Patel
, Alison L. Dickson
, et al.
·
Translational Oncology
·
4
Abstract 1835: NUC-3373 targets the DNA-directed pathway more effectively than 5-FU
2022
·
Jennifer Bré
, Alison L. Dickson
, et al.
·
Cancer Research
·
4
A phosphoramidate modification of FUDR, NUC-3373, causes DNA damage and DAMPs release from colorectal cancer cells, potentiating lymphocyte-induced cell death
2025
·
Oliver J. Read
, Jennifer Bré
, et al.
·
PLoS ONE
·
3
Abstract 1855: NUC-1031 overcomes resistance associated with gemcitabine in cancer patients
2018
·
Jennifer Bré
, Awa Sarr
, et al.
·
Cancer Research
·
2
Abstract 1003: NUC-1031 causes incorporation of fluorinated deoxycytidine into DNA, inducing persistent damage in biliary tract cancer cells
2021
·
Dillum Patel
, Alison L. Dickson
, et al.
·
Cancer Research
·
1
Abstract B026: Targeting the novel tumor antigen MT1-MMP with Bicycle® Drug Conjugates (BDC®) for the potential treatment of NSCLC and other solid tumor indications
2025
·
Steve B. Ludbrook
, Stephen Walsh
, et al.
·
Molecular Cancer Therapeutics
Abstract 1113: NUC-3373 potentiates immune-mediated cytotoxicity of CRC cells
2022
·
Oliver James Read
, Jennifer Bré
, et al.
·
Cancer Research
Abstract P025: NUC-3373 is a more potent inhibitor of thymidylate synthase than 5-FU and reduces generation of toxic metabolites
2021
·
Jennifer Bré
, Alison L. Dickson
, et al.
·
Molecular Cancer Therapeutics
Abstract 1655: NUC-3373 induced DAMPs release in CRC cells promotes natural killer cell activation
2021
·
Oliver James Read
, David James Harrison
, et al.
·
Cancer Research
Abstract 1840: NUC-1031 causes release of DAMPs and upregulates PD-L1 expression in lung cancer cells
2020
·
Jennifer Bré
, Oliver J. Read
, et al.
·
Cancer Research
Exploration of the pharmacodynamic profile of Acelarin, a novel ProTide drug, in an in vitro model of ovarian cancer
2019
·
Bré, Jennifer
·
St Andrews Research Repository (St Andrews Research Repository)
Anticancer activity in patients with advanced ovarian and biliary tract cancers treated with NUC-1031 and a platinum agent.
2019
·
Sarah Patricia Blagden
, Jennifer Bré
, et al.
·
Journal of Clinical Oncology
Abstract 572: Genome-scale CRISPR/Cas9 screen identifies factors required for sensitivity to pyrimidine nucleoside analogs
2018
·
Awa SARR
, Jennifer Bré
, et al.
·
Cancer Research
Genome-scale CRISPR/Cas9 screen identifies factors required for sensitivity to pyrimidine nucleoside analogs
2018
·
Awa Sarr
, Jennifer Bré
, et al.
·
Cancer Research
Show more works
View as search
Works count:
17
Citation count:
75
H-index:
4
I10-index:
3
Year
Topic
Type